ClinicalTrials.gg
DrugBiologicalRead study by study

Nivolumab clinical trials

Also written Opdivo, BMS-936558 and ONO-4538.

Includes 3 studies of Nivolumab and Recombinant Human Hyaluronidase.

studies test it
1,031
open now
178
in phase 3
122
first study started
2006
Related medicines add 2 studies

Counted the way a researcher would: Nivolumab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

ClinicalTrials.gov finds 2,044 studies for Nivolumab. How that becomes 1,031 here

Every study that search finds has been read, to see whether and how it gives Nivolumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 2,044Found by its intervention search · See all 2,044 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 1,755 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −17
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 2,027Give Nivolumab to participants
  4. −229Observe patients on it, or give it outside a trial
  5. −11Use it as a tool: an imaging tracer or a test of drug response
  6. −38Compare another treatment with it
  7. −718Give it beside what is tested
  8. 1,031Test it: the count on this site

Get an email when these change. Save the Nivolumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Dec 2014 · OPDIVO · BLA 125554 (FDA, Drugs@FDA)
European Union
19 Jun 2015 · Opdivo · EMEA/H/C/003985 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Nivolumab
794
NIVO
100
Nivolumab Injection
11
946414-94-4
7
Nivolumab 10 MG/ML
6

Brand

Opdivo
433

Development codes

BMS-936558
214
ONO-4538
130
MDX-1106
122
BMS-936558-01
4
BMS-986298
3
NSC 748726
3
AG013736
2

In one entry with another drug

Given together, or one or the other

Nivolumab and Ipilimumab
6
Nivolumab + Relatlimab
5
Nivolumab + Ipilimumab
5
Nivolumab & Ipilimumab
4
Nivolumab plus Ipilimumab
4
Relatlimab + Nivolumab
2
nivolumab, ipilimumab
2
Opdivo and Yervoy
2

Biosimilars

ABP 206
2
BCD-263
2
CMAB819
1

Studies by the year they started

1,028 studies that test it; most in 2019 (152); 2 more planned to start later

Studies that test Nivolumab, by start year
YearStudies
20061
20082
20092
20102
20113
201212
201310
201422
201551
201682
2017145
2018144
2019152
2020106
202173
202260
202350
202439
202537
202635

By phase

A phase 1/2 study counts in both.

Early Phase 1
17
Phase 1
280
Phase 2
731
Phase 3
122
Phase 4
14
No phase
15

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 167 · Other 864

Bristol-Myers Squibb (128) · National Cancer Institute (NCI) (73) · M.D. Anderson Cancer Center (44) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (27) · Memorial Sloan Kettering Cancer Center (23) · H. Lee Moffitt Cancer Center and Research Institute (19) · The Netherlands Cancer Institute (19) · Dana-Farber Cancer Institute (17)

Often tested with

Tested in the same studies.

Ipilimumab (319) · Pembrolizumab (40) · Cabozantinib (36) · Cisplatin (26) · Relatlimab (25) · Gemcitabine (23) · Paclitaxel (20) · Carboplatin (17)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 20 phase 3 studies under way

Nivolumab is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with Nivolumab beside them; studies of each.

Reaching primary completion within a year · 118, 9 in phase 3

Studies that test Nivolumab, phase 3 first.

Studies

Open first, then newest update. How each study uses Nivolumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 1,031

See all 1,031 studies that test Nivolumab →

Behind its US label · 29 — the studies the FDA label of OPDIVO describes

From the Clinical Studies section of OPDIVO (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 215 — no other medicine in its arm

Showing 20 of 215. See all 215 →

Tested with established drugs · 136 — they are given beside it

Showing 20 of 136. See all 136 →

Tested in a combination · 680 — another drug in the study is under test too

Showing 20 of 680. See all 680 →

Beside an established treatment under test · 112 — an approved drug, surgery or radiation is what the study tests

Tested with Nivolumab: Radiation 33 · Surgery or a procedure 30 · Ipilimumab 12 · cabozantinib 9 · Oxaliplatin 5 · relatlimab 4 · Carboplatin 3 · Cisplatin 2

Showing 20 of 112. See all 112 →

Beside a new treatment under test · 581 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with Nivolumab: relatlimab 18 · linrodostat 12 · sitravatinib 10 · bempegaldesleukin 9 · cabiralizumab 8 · poly ICLC 7 · zanzalintinib 7 · BMS-986310 6

Showing 20 of 581. See all 581 →

Beside supportive care · 17 — a supportive treatment or test is studied
One option of several · 9 — a test or a strategy chooses among drugs
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 38 — what is tested is compared with Nivolumab

Showing 20 of 38. See all 38 →

Observed · 229 — patients on it are followed, or it is given outside a trial

Showing 20 of 229. See all 229 →

As a tool · 11 — an imaging tracer or a test of drug response

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Nivolumab · ClinicalTrials.gg INT006768

  • MeSH (NLM) D000077594NivolumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 31YO63LBSNNIVOLUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1597876Confirmed FDA, Wikidata
  • Wikidata Q7041828nivolumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C68814NivolumabOne source FDA
  • DrugBank DB09035One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion